Alnylam Pharmaceuticals | ALNY - Sales Revenues


Alnylam Pharmaceuticals reported $1.46B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.1B 1.48B Jun/2026
Arrowhead Research USD 75.23M 1.49M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Moderna USD 100M 289M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 13.11B 750M Mar/2026
PTC Therapeutics USD 361M 88M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.14B 65M Mar/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Takeda JPY 1.19T 32.9B Sep/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026